Header a MOSA O2

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

HOME

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

CONTACT

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

3D Map of the Americas - MOSA - Medical Oxygen Society of the Americas

Header Logo - MOSA - Medical Oxygen Society of the Americas
Google Language Translator - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org
   
   
HOME PAGE menu white arrow - MOSA - www.mosao2.org - Medical Oxygen Society of the Americas
NEWS / RESEARCH menu white arrow - MOSA - www.mosao2.org - Medical Oxygen Society of the Americas
   

bg grey mosao2

 
Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org


MOSA - Article

Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org


O3 Ozone - Oxygen Medicine:

O3 Ozone & H2O2 vs Cancer - Science Abstracts & References

Logo - MOSA - Medical Oxygen Society of the Americas

 

Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org

 

O3 Ozone & H2O2 vs Cancer - Science Abstracts and References

 

Aronoff, B. L. (1965) ""Regional Oxygenation in Neoplasm."
Cancer. Vol 18.

Gerson, Max. (1990) A Cancer Therapy. Bonita, CA: Gerson
Institute/Pulse.

Samoszuk, M.K. et.al. (1989) "In Vitro Sensitivity of Hodgkins
Disease to Hydrogen Peroxide," Cancer. Vol. 63.

Sasaki, H., et. al. (1967) "Application of Hydrogen Peroxide
to Maxillary Cancer," Yonago Acta Medica Vol. 11/3. 109.

Sweet, F. et. a;. (1980) "Ozone Selectivity Inhibits Growth of
Cancer Cells." Science. Aug 22. 931-932.

Varro, J. (1983) "Ozone Apllications in Cancer Cases, " Medical
Applications of Ozone. Norwalk, Conn: International Ozone
Association, Pan American Committee.

Warburg, Otto.(1966) The Prime Cause and Prevention of Cancer.
Wurzburg: K. Triltsch.

Grunder, H.G., E. Bauer, G. Tramer, E. Utesch. (1976)
"Intravenous Ozone in Irradiated and Non-Irradiated Tumors in Mice."
Strahlenther, Vol151. 151-154, 480-486,522-529.

Hernuss, P. (1973) "The Effects of Ozone in RadioTherapy for
Tumors in Animal Experiments." Fortschr auf dem Geb der Roentgenstr
und der Nuklearned.Suppl. 196.

Nathan, C.F. and Z. A. Cohn. (1981) "Antitumor Effects of
Hydrogen Peroxide in Vivo," Journal of Experimental Medicine. Vol.
149.

Paulesu, L., Luzzi, E., Bocci, V., (1990) "Studies on the
Biological Effects of Ozone: Induction of Tumor Necrosis
Factor (TNF-a) on Human Leukocytes. Lymphokine and Cytokine
Research. Vol. 10.5: 409-412.

Teske, H.J., J. Haller, B. Badenber, G. Hoppe (1972)
"Studies of the Effect of Ozone on Tumor Growth and the Action of
Irradiation." Deutschr. Roentgenkongr. (Stuttgart)

 

TI Regional hyperoxygenation: an important factor in the
potentiation of antineoplastic chemotherapy
AU Nervi-C; Casale-C; Cortese-M
SO Tumori. 1969 May-Jun; 55(3): 153-9
ISSN 0300-8916
LA ITALIAN


TI Combined therapy of intra-arterial injection of hydrogen
peroxide solution and irradiations in maxillary cancer
AU Sasaki-H; Wakuya-T; Oda-K; Yamazaki-Y
SO Nippon-Jibiinkoka-Gakkai-Kaiho. 1971 Feb; 74(2): 398-9
ISSN 0030-6622
LA JAPANESE


TI Studies on the effect of ozone on tumor growth and radiation
effect (animal experiments)
AU Teske-HJ; Haller-J; Badenberg-B; Hoppe-G
SO Fortschr-Geb-Rontgenstr-Nuklearmed. 1972: Suppl:12-4
ISSN 0015-8151
LA GERMAN


TI Effect of ozone in radiotherapy for malignant tumors in the
animal experiment
AU Hernuss-P; Muller-Tyl-E; Seitz-W
SO Fortschr-Geb-Rontgenstr-Nuklearmed. 1973; 0(0): suppl:196
ISSN 0015-8151
LA GERMAN


TI Ozone and gynecologic radiotherapy
AU Hernuss-P; Muller-Tyl-E; Wicke-L
SO Strahlentherapie. 1975 Nov; 150(5): 493-9
ISSN 0039-2073
LA GERMAN
CP GERMANY,-WEST
UI 76130722

 

Abstract

Ozone is used in medicine as well as
in other spheres. Papers reporting good results of ozone treatment in
carcinoma seemed of particular interest. The efficacy of ozone as an
adjuvant to the irradiation of carcinosarcomas of rats was confirmed
by us. On account of this fact ozone was introduced by us as an
adjuvant to the irradiation of women with gynaecological cancer and
appeared to give good results. The mechanism of action of ozone is
not yet fully clarified and several theories are discussed.
Investigations are currently being undertaken in respect to the
behaviour of several substances in the organism during ozone therapy.



TI Animal experiments on the use of ozone in irradiated and non-
irradiated tumors. III. Ehrlich-ascite carcinoma cells in vitro
AU Grundner-HG
SO Strahlentherapie. 1976 May; 151(5): 480-6
ISSN 0039-2073
LA GERMAN
CP GERMANY,-WEST
PT JOURNAL-ARTICLE
UI 76199988

 

Abstract

Measurements carried in vitro were carried out concerning the
effectof ozone either by itself or combined with X-ray therapy
(single dose of 2000 R) on the reproductive capacity of Ehrlich-
ascites cancer cells. The strongest combination effect is stated when
ozone is administered after irradiation. The findings and results of
this study are compared with hypotheses and results described in the
corresponding literature.





In one study,[58] cultured cells of different carcinoma types
were compared with non-cancerous human lung fibroblasts on
exposure to ozonated air (0.3, 0.5, and 0.8 ppm of O3 for 8
days). Alveolar (lung) adenocarcinoma, breast adenocarcinoma,
uterine carcinosarcoma and endometrial carcinoma showed 40% cell
growth inhibition at 0.3 ppm and 60% at 0.5 ppm. The
non-cancerous lung cells were unaffected at these levels. In 0.8
ppm exposure, cancer cell growth inhibition was 90%.
Interestingly, it was at this level that the control cell group
started to manifest anabolic slowdown (50%). The authors
postulate that cancer cells are less able to compensate for the
oxidative challenge of ozone than normal cells, possibly by way
of a less functional glutathione system.
58. Sweet J, Kao MS, Lee D, Hagar W: Ozone selectively inhibits
growth of human cancer cells. Science 1980;209:931-933.


---------------------------------------


Five States Pass Laws Protecting Medical Doctors Who Practice
Alternative Therapies

On July 26, 1994, New York state passed an Alternative Medical
Practices Act, thereby joining Alaska, North Carolina, Washington and
Colorado. The new state laws protect medical doctors who practice
alternative therapies, such as ozone and EDTA from losing their
licenses. The New York law requires that at least two members of the
State Board for Professional Medical Conduct must be Physician-
practitioners of non-conventional medicine. The New York law was
designed to prevent a repeat of cases like the years of investigation
and harassment of Dr. Warren Levin, M.D. for his unconventional
treatment modalities (vitamin and mineral therapies, EDTA chelation
and other orthomolecular therapies). After 13 years of investigation
and harassment, Dr. Warren was cleared of all charges. Other high
profile cases were Dr. Emmanual Rivici, M.D. and Dr. Robert Atkins
M.D. Dr. Atkins had his licence suspended for using ozone on a cancer
patient that other doctors had given up on after using all the
radiation and chemotherapy her body could take. When Dr. Atkins had
his licence reinstated by a State Judge, the judge said: "I have never
seen a such capricious and malicious act by a regulatory agency over a
matter as inconsequential."

 

1992: In North Carolina, Dr. John Pittman M.D. was threatened with the
loss of his medical licence if he continued using ozone therapy on his
AIDS patients. He moved his clinic to Haiti for awhile in 1993, then
closed it down due to the deteriorating political situation in that
country. After North Carolina passed an Alternative Medical Practices
Act early in 1994, Dr. Pittman was advised by the Medical Board, that
he could come back to North Carolina and practice ozone therapy. Dr.
Pittman opened "The Carolina Center for Bio-Oxidative Medicine," in
Raleigh, NC in October, 1994 and has resumed offering Ozone Major
Autohemotherapy for PWA's. His phone number is 800-539-9812 or 704-
857-0073. In Spartanburg, South Carolina, Dr. H. Fudenberg M.D. has
offered ozone and has done ozone research for PWA's for some time.
Dr. Fudenberg monitors T4 counts weekly and adjusts concentration and
dosage of ozone to attain maximum buildup of the T4 counts. He can be
reached at 803-576-0988. Dr. Frank Shallenberger M.D. continues to
offer ozone therapy in Minden, NV (702-782-4164).

 


------------------------------------------------

 

from THE AMERICAN CANCER SOCIETY.....(a bogus organisation run by
drug company co-horts)

UI - 93137111

TI - Questionable methods of cancer management: hydrogen peroxide and
other 'hyperoxygenation' therapies.
AB - Hyperoxygenation therapy--also called oxymedicine,
bio-oxidative therapy, oxidative therapy, and oxidology--is
a method of cancer management based on the erroneous concept that
cancer is caused by oxygen deficiency and can be cured by
exposing cancer cells to more oxygen than they can tolerate. The
most highly touted hyperoxygenating agents are hydrogen
peroxide, germanium sesquioxide, and ozone. Although these
compounds have been the subject of legitimate research, there is
little or no evidence that they are effective for the treatment
of any serious disease, and each has demonstrated potential for
harm. Therefore, the American Cancer Society recommends that
individuals with cancer not seek treatment from individuals
promoting any form of hyperoxygenation therapy as an
alternative to proven medical modalities.



------------------------------------------------



In the Federal Register of 2/13/76, the Federal Drug
Administration (FDA) asserted that "Ozone is a toxic gas with no
known medical uses."



Ozone Selectively Inhibits Growth of Human Cancer Cells
Science Vol. 209, 22 Aug 1980, pp. 931-933
Abstract:

The growth of human cancer cells from lung, breast, and uterine
tumors was selectively inhibited in a dose-dependent manner by
ozone at 0.3 to 0.8 part per million of ozone in ambient air
during 8 days of culture. Human lung diploid fibroblasts served
as noncancerous control cells. The presence of ozone at 0.3 to
0.5 part per million inhibited cancer cell growth 40 and 60
percent, respectively. The non-cancerous lung cells were
unaffected at these levels. Exposure to ozone at 0.8 part per
million inhibited cancer cell growth more than 90 percent and
control cell growth less than 50 percent. Evidently, the
mechanisms for defense against ozone damage are impaired in
human cancer cells.
We have conducted experiments in which continuous exposure to ozone at 0.3
ppm
(6) selectively inhibited the growth of human cancer cells 40 percent in 8
days.

Controlled levels of ozone (0.3 to 0.8 ppm) were continuously
generated by ultraviolet irradiation of filtered ambient air.
The ozonated air, containing 5 percent carbon dioxide, was
introduced at a constant flow rate of 4.0 liter/min into an
environmental chamber in an incubator maintained at 37 degrees
Celsius (Fig. 1) For comparison, noncancerous
human lung diploid fibroblasts (7) were cultured in the chamber
along with the cancer cells. The cancer cells were from
alveolar (lung) adenocarcinomas (8), breast adenocarcinomas (9),
uterine carcinosarcomas, and endometrial carcinomas (10).

 

All of the cancer cells showed marked dose-dependent growth inhibition in
ozone at 0.3 and 0.5 ppm (Fig 2.). There was no growth inhibition of the
noncancerous lung cells at these ozone levels, and they were
morphologically identical to the corresponding control cells.
At 0.8 ppm, the growth of the noncancerous cells was inhibited
50 percent, but all four types of cancer cells were inhibited
more than 90 percent.

 

However, in ozone at 0.5 ppm, all of the human cancer cells (which do not age)
had growth rates several times lower than that of the aged, noncancerous
cells (Fig 2.).

Evidently, cancer cells are less able to compensate for the
oxidative burden of ozone than normal cells.
These findings lead us to believe that ozone--alone, in
combination with radiation therapy (16), or in chemotherapy
utilizing electrophilic compounds (17)--may have therapeutic
value for patients with certain forms of lung cancer.

 

Frederick Sweet
Ming-Shian Kao
Song-Chiau D. Lee
Department of Obstetrics and Gynecology, Washington University
School of Medicine, St. Louis, Missouri, 633110.

 

6. Normal human subjects tolerated breathing 0.5 ppm ozone in
air 2 hours per day for 1 week or 0.25 ppm ozone 2 hours per
day for 3 weeks (4). The two groups engaged in light
exercise during exposure. Although both groups developed
chest discomfort and moderately decreased respiratory
function during exposure, their removal from the oxidative
environment resulted in rapid disappearance of the symptoms.
The mean dose-response curves from this study show a no-
detectable-effect level at 0.25 to 0.30 ppm. A similar
study (3) found that human subjects tolerated exposure to
0.5 ppm ozone for up to 6 hours. Pulmonary function was
affected and chest discomfort developed at this level, with
no significant differences observed between smokers and
nonsmokers.

 

 

________________________________________

 

 

 

   

 

 

Copyright @ 2011 www.mosa02.com. All Rights Reserved.


Disclaimer:

While every effort has been made to ensure that the information and data provided on this website are correct, no guarantee can be provided that
the information it contains is completely error-free. MOSA shall not be held liable for information and data that is not up-to-date, correct or complete.

MOSA reserves the right to edit, change or add to the information and data provided without prior notice. This website is produced and published
so that you can broaden your health education and options. Please consult your physician before considering any therapy.